Fighting counterfeit medicines in Europe: the effect on access to medicines

14 September 2017

Policy

The implementation of the Falsified Medicines Directive, and its Delegated […]

US FDA Advisory committee hears first-hand about the decade of EU experience with biosimilar medicines use

13 July 2017

Policy

Medicines for Europe Director General Adrian van de Hoven participated […]

Letter from European and UK Life Sciences Organizations Underlining the Importance of Securing Ongoing Cooperation Between the UK and EU on Medicines

13 July 2017

Policy

Position Paper External Reference Pricing for Generic and Biosimilar Medicines

1 July 2017

Policy

Medicines for Europe Country Specific Market Access Policies

23 May 2017

Policy

ISPOR 2016 EU – Value Added Medicines

18 November 2016

Policy, Report

Healthcare System Inefficiencies Related To Medicines: Any Potential Room For […]

Essential Medicines for Universal Health Coverage

7 November 2016

Policy

Medicines for Europe’s Contribution to WHO’s Biological Qualifier (BQ) Developments (PRESENTATION and SPEECH)

18 October 2016

Policy

      18 October 2016 Suzette Kox Senior Director […]

Understanding the Science of Extrapolation and Defining Interchangeability – Dr. Elena Wolff-Holz, EULAR Symposium London

10 June 2016

Policy

Value Added Medicines: Rethink, Reinvent & Optimize Medicines, Improving Patient Health & Access

31 May 2016

Policy, Report